19 results
424B5
ANVS
Annovis Bio Inc
1 May 24
Prospectus supplement for primary offering
4:50pm
, including about adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement
424B5
ANVS
Annovis Bio Inc
18 Mar 24
Prospectus supplement for primary offering
10:00pm
adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory
424B5
ANVS
Annovis Bio Inc
18 Mar 24
Prospectus supplement for primary offering
8:51pm
adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory
424B5
ANVS
Annovis Bio Inc
1 Nov 23
Prospectus supplement for primary offering
12:24pm
direct competitors, including about adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns … confidence and raise reputational issues and may subject us to additional risks and uncertainties, including increased professional costs and the increased
424B5
6275 ts08jh0fdcj
30 Oct 23
Prospectus supplement for primary offering
5:27pm
10-K
rajkzd 7hv
25 Mar 20
Annual report
4:45pm
424B4
284o cbm0bkkjstaca
30 Jan 20
Prospectus supplement with pricing info
6:07am
S-1/A
tfaqdqpnge21nrc6pjp
8 Aug 19
IPO registration (amended)
5:23pm
S-1
sp36h0f
2 Jul 19
IPO registration
9:15pm
DRS/A
zxjfddc f4t9fua
24 May 19
Draft registration statement (amended)
12:00am
DRS
i6reswo9agqc
15 May 19
Draft registration statement
12:00am
- Prev
- 1
- Next